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Background: Among malignancies, lung cancer is a leading cause of death. Platinum-based therapeutic compounds used to treat 
lung cancer have not been able to increase the survival of patients and such compounds have a high incidence of adverse and toxic 
effects. It has been proposed that flavonoids such as catechins may significantly reduce the risk of developing cancer, alongside 
with other health benefits. The aim of this work was to determine the effect of (-)-epicatechin, the main flavanol found in cocoa, 
on the proliferation of the lung non-small cell adenocarcinoma cancer cell line A549, and to determine its effects when added si-
multaneously with cisplatin. Materials and Methods: Concentration-response curves for cisplatin and epicatechin were obtained, 
inhibitory concentrations calculated and an isobolographic analysis was then performed. Results: We found that epicatechin has 
a concentration-dependent inhibitory effect on proliferation of tumor cells and the isobolographic analysis reveals that the effect 
of its combination with cisplatin is synergistic. It was also observed that epicatechin promotes cell death by apoptosis. Conclusions: 
Epicatechin might be considered for future studies to explore its possible use as coadjuvant in cisplatin-based treatments.
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Among malignancies� lung cancer �as t�e �ig�er 
morbidity and mortality worldwide [�]. According 
to t�e American Lung Association� 5-year survival 
rate is just �7.�%� compared to ot�er types of can-
cers as colon �65.�%�� breast ���.5%� and prostate 
���.6%� [�]. Only �5% of cases are diagnosed in early 
stages.
T�e treatment depends on t�e type and stage 
of cancer and includes surgery� c�emot�erapy 
and radiot�erapy. Adjuvant platinum-based c�e-
mot�erapy �cisplatin or carboplatin� is t�e most 
common c�oice� �owever� t�e response rate is not 
�ig�. In addition� cisplatin causes nep�rotoxicity� 
gastrointestinal toxicity� myelosuppression� oto-
toxicity and neurotoxicity. So� t�e use of cisplatin 
leads to comorbilities of difficult control� because 
no agent conferring protection against t�ese toxic 
effects �as been developed [�].
T�e primary cellular effect of cisplatin is to form 
adducts or crosslinks in DNA [�]. In vitro studies 
�ave s�own t�at interaction between cisplatin and 
DNA may contribute to t�e generation of super-
oxide radicals causing toxicity in cancer cells [5]. 
DNA damage activates DNA-repair mec�anisms 
and apoptosis t�roug� activation of t�e tumor sup-
pressor protein P5�. Lung cancer �as a �ig� rate 
of TP53 mutations �in �6% of adenocarcinomas and 
in ��% of squamous cell carcinomas [6]� decreasing 
response rate [7].
In t�is context� t�ere is an urgent need to searc� for 
t�erapeutics t�at may increase efficacy and reduce t�e 
adverse effects of t�e current c�emot�erapy in lung 
cancer.
Several epidemiological studies �ave suggested 
t�at a diet ric� in fruits and vegetables is associated 
wit� reduced risk of cancer [�� �]. In t�is regard� 
cocoa �T�eobroma cacao� is particularly interest-
ing because it is a fruit w�ose seeds and deriva-
tives� ric� in bioactive compounds wit� remarkable 
beneficial effects on metabolism and cardiovas-
cular system� are worldwide consumed [��]. One 
of suc� bioactive compounds of cacao is t�e flavanol 
�-�-epicatec�in �EC�. Alt�oug� many aut�ors refer 
to it as an inert compound� EC �as s�own anti-
proliferative activity in stomac�� prostate and ovary 
cancer [��� ��]. Regarding lung cancer� it �as been 
noted t�at in adenocarcinoma cells A5�� and PC-�� 
EC is able to potentiate t�e growt�-in�ibitory effect 
and to increase apoptosis induced by t�e polyp�enol 
curcumin [��] suggesting t�at EC may �ave a poten-
tiating effect in cancer treatment. It is also known t�at 
EC reduces nep�rotoxicity [��] and ototoxicity [�5] 
induced by cisplatin so it seems to be an excellent 
option to reduce t�e toxic effects of conventional 
c�emot�erapies.
T�e aim of t�is study was to investigate t�e ef-
fect of EC in combination wit� cisplatin in A5�� lung 
adenocarcinoma cells� assessing w�et�er suc� com-
bination ac�ieves an additive effect on cytotoxicity.
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MATERIALS AND METHODS
Cell lines. Hel-��� cells derived from �uman 
embryonic lung tissue and lung adenocarcinoma 
A5�� cells were cultured under standard conditions 
wit� 5% CO� at �7 °C. Cells were treated wit� different 
concentrations of cisplatin [CDDP �cis-Diammineplat-
inum �ii� dic�loride� Sigma�] ������ µ�� or �-�-epica-
tec�in �EC� Sigma� ��.������ µ�� or t�e combination 
of bot� compounds for �� �. Bot� compounds were 
dissolved in D�SO ��.�%�.
Cell viability. Cell viability was determined by �TT 
assay. Briefly� cell were incubated wit� �.� mg/ml �TT 
��-���5-dimet�yl-�-t�iazolyl�-��5-dip�enyltetrazolium 
bromide� during �� min at �7 °C. Purple formazan 
formed was solubilized using �.�� � HCl-isopropanol. 
T�e dissolved material was measured spectrop�oto-
metrically at 5�5 nm �BioteckSynergy HT� USA�. Eac� 
experiment was made in triplicate in independent 
assays �n = 5�. Percent of cell viability was calculated 
as t�e ratio of t�e optical density in experiment to t�e 
optical density in control.
Isobolographic analysis. We plotted concentra-
tion — deat� curves for EC and CDDP using Grap�-
Pad Prism 5 software� afterwards an isobolograp�ic 
analysis was provided. Briefly� after t�e in�ibitory con-
centrations �IC� for eac� compound were calculated� 
t�eoretical values �e.g. IC��� IC�5� of combinations 
in a fixed �:� ratio were obtained according to t�e 
equation �Eq. ����.
Equation ���
CDDP Theoretical
ICX
+ =1
EC Theoretical
ICX
If an additive effect exists� ½ EC effective con-
centration plus ½ CDDP effective concentration must 
be equal to �. As an example� in a combination ½ EC 
�IC��� + ½ CDDP �IC���� if an additive effect exists t�ere 
will be a ��% in�ibition of cell growt�.
In order to determine if t�e t�eoretical analysis 
corresponds to real effects in cells� t�e interaction 
of EC wit� CDDP was t�en experimentally evaluated 
by t�e simultaneous administration of ½ EC �ICx� + 
½ CDDP �ICx� concentrations� w�ere ICx corresponds 
to different concentrations of compounds �we always 
used a �:� ratio�. T�e experimental results obtained 
wit� t�e combinations employed were analyzed wit� 
equation � ascertaining t�e type of interaction be-
tween t�e two compounds:
Equation ���
IC30
+ = ResultIC30
CDDPExperimental ECExperimental 
W�en t�e analysis produces a result equal 
to �� t�ere is an additive effect. If t�e result is < �� 
t�ere is a synergism or supra-additive effect and� 
if t�e result is > � t�e interaction between compounds 
is antagonistic.
Acridine orange/ethidium bromide stain-
ing. T�e cells cultured on glass cover slips were 
stained wit� acridine orange/et�idium bromide 
��5 µ�/�.��� µ��. For image display and acquisition� 
a fluorescence microscope �Nikon E6�� Eclipse� was 
used. Images of 5 randomly selected fields were taken 
and t�e intensity of green and red fluorescence was 
measured using t�e ImageJ software version �.��x 
��ttp://rsb.info.ni�.gov/ij� developed by Wayne Ras-
band� National Institutes of Healt�� Bet�esda� �D� 
USA�. A brig�t green color was observed in live cells 
w�ile t�e cells in apoptosis and dead cells s�owed 
a brig�t red color.
RESULTS
Cell viability. T�e results indicate t�at t�e 
CDDP in�ibits t�e growt� of Hel-��� �Fig. �� a� and 
A5�� �Fig. �� cells in a concentration dependent man-
ner. EC does not in�ibit proliferation of Hel-��� cells 
�Fig. �� b� �owever� in A5�� cells� EC induces a con-
centration dependent in�ibitory effect �Fig. ��. From 
t�e aforementioned curves� we calculated IC �IC��� for 
eac� compound.
Fig. 1. Growt� in�ibition of Hel-��� cells: a� by cisplatin; 
b� by EC. Data are expressed as mean ± SE�. Linear regression 
curves were obtained using Grap�pad Prism software
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Fig. 2. Growt� in�ibition of A5�� cells by cisplatin. Data are ex-
pressed as mean ± SE�. Linear regression curve was obtained 
using Grap�pad Prism software
Fig. 3. Growt� in�ibition of A5�� cells by EC Linear regression 
curve obtained using Grap�pad Prism software. Data are ex-
pressed as mean ± SE�
Isobolographic analysis. After t�e IC for eac� 
compound were calculated� t�e t�eoretical IC�� values 
of combinations in a fixed �:� ratio were obtained ac-
cording to equation ���.
0.825 µM
IC30 [1.65 µM]
+ =1IC30 [4.27 µM]
2.135 µM
T�en� t�e effects of combinations of one �alf 
of IC�� were explored experimentally and t�e result 
analyzed using equation ��� and plotted.
0.218 µM
IC30 [1.65 µM]
+ =0.26IC30 [4.27 µM]
0.546 µM
We found t�at t�e combination of bot� com-
pounds induces growt�-in�ibitory effect superior 
to t�at expected in case of t�e additivity �Fig. ��� t�e 
isobolograp�ic analysis results in an effect < � ��.�6� 
w�en plotted below t�e line of additivity �Fig. 5�. T�e 
effect is �ig�ly significant �p = �.����� indicating t�e 
synergistic antiproliferative effect of t�e combination 
of bot� compounds in A5�� cells.
Fig. 4. Individual effects of IC7.5 and IC�5 of cisplatin and EC and 
t�e increased effect w�en bot� compounds are combined. Data 
are expressed as mean ± SE�
Fig. 5. Grap�ic representation of isobologram of growt�-in�ibit-
ing effect of cisplatin and EC combined. T�eoretical dotted line 
represents interaction if effects were additive. Experimentally 
obtained values s�ow a synergistic interaction
Cell death. Results s�owed t�at t�e cell dam-
age produced by t�e treatments wit� CDDP and/
or EC is apoptotic. Upon staining wit� wit� acridine 
orange/et�idium bromide we analyzed and counted 
viable �green fluorescence� and dying �orange fluo-
rescence� cells. Late apoptotic cells wit� condensed 
and fragmented nuclei stained by et�idium bromide 
are seen in specimens treated wit� CDDP� EC� or bot� 
suggesting t�e apoptotic mode of deat� �Fig. 6�. �ore-
over� combination of bot� compounds increased t�e 
apoptotic percentage of A5�� cells compared to t�at 
of CDDP or EC used as single agents �see Fig. 6�.
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Fig. 6. Identification of cell deat� after �� � treatment wit� com-
pounds alone or in combination �acridine orange and et�idium 
bromide staining�. Viable cells �green� and cells dying �orange� 
are s�own �arrows indicate cells in apoptosis�. Grap�ic repre-
sentation of fraction of cells in apoptosis
DISCUSSION
EC belongs to a class of polyp�enols� t�e flavanols. 
It is commonly found in natural products like cacao 
and cacao products suc� as dark c�ocolate� and also 
in green tea. EC-induced effects seem to be specific 
since structurally related isomers �catec�in� �-�-epigal-
locatec�ingallate �EGCG�� etc� [�6� �7] do not induce 
similar effects or even act as antagonists of EC ef-
fects [�6].
Antiproliferative activity of EC �as been s�own 
in stomac� [��]� prostate and ovary [��] cancer and 
adenocarcinoma cells A5�� and PC-� �lung cancer�. 
It in�ibits t�e proliferation of Hodgkin’s lymp�oma 
cells and Jurkat T cells� effect attributed to its ability 
to in�ibit t�e binding of NF-κB to DNA [��]. Interest-
ingly� EC causes DNA damage and apoptosis in acute 
myeloid leukemia cells in rats [��].
T�e interest in studying EC effects in lung can-
cer cell is based on reported EC in�ibitory effects 
on proliferation of cancer but not normal cells [��� 
��]. Our results �ave s�own t�at EC induced a con-
centration dependent in�ibition of proliferation 
of lung cancer cell A5��� wit�out in�ibition of pro-
liferation of normal lung cells �Hel ����.
One possible mec�anism of EC action is t�e in�ibi-
tion of t�e Na+/H+ exc�anger� in t�is way cell plasma 
membrane fluidity and cytosolic pH are disturbed� 
t�us interfering wit� cell proliferation [��]. Ot�er 
mec�anisms proposed are acting t�roug� Erk and/
or ot�er signaling pat�ways leading to an activation 
of mitoc�ondrial oxidative p�osp�orylation� w�ic� 
interferes wit� Warburg metabolism decreasing t�e 
non-oxidative breakdown of glucose and increasing 
t�e mitoc�ondrial dependent oxidative breakdown 
of pyruvate. Interestingly� we and ot�ers �ad been 
s�own t�at EC induce mitoc�ondrial biogenesis in vitro 
and in vivo [�����]. T�roug� t�ese processes EC could 
interfere wit� cancer signaling� t�us rendering t�e cells 
more susceptible to apoptosis� an effect t�at could 
be utilized to sensitize cancer cells to c�emot�erapy.
EC-induced effects are not limited to in�ibition 
of proliferation� t�ey extend to protective effects 
decreasing toxic effects of c�emot�erapeutic drugs 
in �ealt�y tissues. It �as been reported t�at EC in�ibits 
mitoc�ondrial and renal damage induced by cisplatin 
administration in mice [��].
On t�e ot�er �and� it is well known t�at CDDP 
forms adducts or crosslinks in DNA� in�ibiting replica-
tion [�]� contributing to t�e generation of superoxide 
radicals and causing toxicity in cancer cells [5]. DNA 
damage in turn activates DNA-repair mec�anisms and 
apoptosis t�roug� activation of t�e tumor suppressor 
protein P5�. Alt�oug� t�ere are several described ways 
to develop resistance to cisplatin treatment� mutations 
in t�e TP53 gene �encoding t�e P5� protein� �ave 
an important role in most cancer types and lung cancer 
�as a �ig� rate of specific mutation of TP53� so t�eir 
response to treatment is poor [7].
Wit� all t�ese data in mind� t�e purpose of t�e 
present work was to analyze possible additive anti-
proliferative effects of t�e combination of CDDP and 
EC. We used a p�armacological approac� based 
on t�e analysis of t�e curves of concentration de-
pendent in�ibition of proliferation for CDDP and EC� 
from w�ic� in�ibitory concentrations were calculated. 
We use an isobolograp�ic analysis in order to pre-
cise t�e effects of t�e combination of CDDP wit� 
EC in A5�� cells [��]. In t�e present study we dem-
onstrate t�at co-treatment of A5�� cells wit� CDDP 
plus EC �in a fixed �:� ratio� induced a significant syn-
ergistic effect. �oreover� we �ave s�own t�e increase 
in apoptotic cell fraction upon t�e combined treatment 
as compared to CDDP or EC administered alone. 
We suggest t�at even if EC and CDDP act in different 
ways� t�e convergent pat�ways lead to t�e in�ibition 
of cell growt� and t�e increase in apoptosis.
In addition� t�e synergism observed between CDDP 
and EC contributes to t�e knowledge of t�e importance 
of diet ric� in flavonoids in cancer prevention and 
improved response to treatment [�5]. T�e findings 
reported �ere warrant t�e implementation of trials 
using EC as adjuvant in t�e treatment of non-small 
cell lung carcinoma increasing t�e cytotoxic effect 
of cisplatin on malignant cells� protecting normal cells 
and per�aps reducing secondary effects. We believe 
t�at t�e synergistic effect can set t�e base for more 
complex studies including clinical trials in searc� for 
t�e decrease of cisplatin-induced secondary or toxic 
effects. Finally� EC may be expected to use as co-
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adjuvant of traditional c�emot�erapy �elping to reduce 
dosing or at least reducing secondary effects.
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